IGC Pharma (IGC) Non Operating Interest Expenses (2010 - 2017)

IGC Pharma (IGC) has reported Non Operating Interest Expenses for 8 consecutive years, with $60527.0 the latest figure, recorded in Q4 2017.

• On a quarterly basis, Non Operating Interest Expenses rose 30.26% year-over-year to $60527.0 in Q4 2017; TTM through Dec 2017 was $232948.0, a 33.05% increase from a year earlier, with the FY2017 full-year figure at $223464.0, up 4.46% from the prior year.
• Non Operating Interest Expenses was $60527.0 for Q4 2017 at IGC Pharma, up from $40832.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $504932.0 in Q1 2013 and troughed at $33928.0 in Q1 2016.
• A 5-year average of $83559.4 and a median of $60848.5 in 2014 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses jumped 1880.46% in 2013 and plunged 88.5% in 2014, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $52502.0 in 2013, then advanced by 18.01% to $61957.0 in 2014, then declined by 17.68% to $51000.0 in 2015, then slipped by 8.89% to $46465.0 in 2016, then surged by 30.26% to $60527.0 in 2017.
• The last three Non Operating Interest Expenses figures came in at $60527.0 (Q4 2017), $40832.0 (Q3 2017), and $44546.0 (Q2 2017), per Business Quant data.